Thelansis

 Neutropenia is a serious adverse effect frequently associated with cancer chemotherapy. Loss of neutrophils causes disruption of immune defense mechanisms and increases the likelihood for infections. Infections lead to fever known as febrile neutropenia (FN). Neutrophils generally comprise approximately half to two-thirds of all white blood cells (immune cells) and protect against bacterial infections. Patients who develop neutropenia may have a higher-than-normal risk of infections, and the severity of subsequent infections is also higher. Chemotherapeutic agents act on the bone marrow, where active cell division occurs, and deplete hematopoietic stem cells, leading to a decreased circulating absolute neutrophil count. Patients receiving chemotherapy have been reported to experience a temporary reduction in their neutrophil counts. Chemotherapy-induced neutropenia (CIN) remains a common dose-limiting toxicity for chemotherapeutic agents, causing treatment delays and/or dose reduc...

 Neutropenia is a serious adverse effect frequently associated with cancer chemotherapy. Loss of neutrophils causes disruption of immune defense mechanisms and increases the likelihood for infections. Infections lead to fever known as febrile neutropenia (FN). Neutrophils generally comprise approximately half to two-thirds of all white blood cells (immune cells) and protect against bacterial infections. Patients who develop neutropenia may have a higher-than-normal risk of infections, and the severity of subsequent infections is also higher. Chemotherapeutic agents act on the bone marrow, where active cell division occurs, and deplete hematopoietic stem cells, leading to a decreased circulating absolute neutrophil count. Patients receiving chemotherapy have been reported to experience a temporary reduction in their neutrophil counts. Chemotherapy-induced neutropenia (CIN) remains a common dose-limiting toxicity for chemotherapeutic agents, causing treatment delays and/or dose reduc...